The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
Open accessAbstract
Chimeric antigen receptors (CARs) have been used to redirect the specificity of autologous T cells against leukemia and lymphoma with promising clinical results. Extending this approach to allogeneic T cells is problematic as they carry a significant risk of graft-versus-host disease (GVHD). Natural killer (NK) cells are highly cytotoxic effectors, killing their targets in a non-antigen-specific manner without causing GVHD. Cord blood (CB) offers an attractive, allogeneic, off-the-self source of NK cells for immunotherapy. We transduced CB-derived NK cells with a retroviral vector incorporating the genes for CAR-CD19, IL-15 and inducible caspase-9-based suicide gene (iC9), and demonstrated efficient killing of CD19-expressing cell lines and primary leukemia cells in vitro, with marked prolongation of survival in a xenograft Raji lymphoma murine model. Interleukin-15 (IL-15) production by the transduced CB-NK cells critically improved their function. Moreover, iC9/CAR.19/IL-15 CB-NK cells were readily eliminated upon pharmacologic activation of the iC9 suicide gene. In conclusion, we have developed a novel approach to immunotherapy using engineered CB-derived NK cells, which are easy to produce, exhibit striking efficacy and incorporate safety measures to limit toxicity. This approach should greatly improve the logistics of delivering this therapy to large numbers of patients, a major limitation to current CAR-T-cell therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Adaptive immune features of natural killer cells
Sun, J. C., Beilke, J. N., & Lanier, L. L. (2009) · Nature · doi:10.1038/nature07665 · Cited by 1,619
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512 · cited 3×
“To counteract excessive toxicity mediated by the release of inflammatory cytokines by transduced CB-NK cells, we incorporated a suicide gene (iC9) into our construct.(21) The addition of as little as 10 nM of the small molecule dimerizer AP1903 to cultures of iC9/ CAR.”
InfluentialSelf-citationSchwartz, R. H. (1992) · Cell · doi:10.1016/s0092-8674(05)80055-8 · Cited by 1,293
Toxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Lopez-Vergès, S., Milush, J. M., Pandey, S., York, V. A., Arakawa-Hoyt, J., Pircher, H., Norris, P. J., Nixon, D. F., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-04-282301 · Cited by 752
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Self-citationAdoptive-cell-transfer therapy for the treatment of patients with cancer
Dudley, M. E., & Rosenberg, S. A. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1167 · Cited by 660
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Self-citationTargeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Lanier, L. L., O'Fallon, S., Somoza, C., Phillips, J. H., Linsley, P. S., Okumura, K., Ito, D., & Azuma, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.97 · Cited by 480
Tagaya, Y., Bamford, R. N., DeFilippis, A. P., & Waldmann, T. A. (1996) · Immunity · doi:10.1016/s1074-7613(00)80246-0 · Cited by 440
Cooley, S., Trachtenberg, E., Bergemann, T. L., Saeteurn, K., Klein, J., Le, C. T., Marsh, S. G. E., Guethlein, L. A., Parham, P., Miller, J. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-171926 · Cited by 434
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Zhang, Y., Wallace, D. L., De Lara, C. M., Ghattas, H., Asquith, B., Worth, A., Griffin, G. E., Taylor, G. P., Tough, D. F., Beverley, P. C. L., et al. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02573.x · Cited by 376
Foley, B., Cooley, S., Verneris, M. R., Curtsinger, J., Luo, X., Waller, E. K., Anasetti, C., Weisdorf, D., & Miller, J. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201964 · Cited by 369
On guard—activating NK cell receptors
Lanier, L. L. (2001) · Nature Immunology · doi:10.1038/83130 · Cited by 346
Goulmy, E. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb00978.x · Cited by 331
Vera, J., Savoldo, B., Vigouroux, S., Biagi, E., Pule, M., Rossig, C., Wu, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017061 · Cited by 275
Self-citationStringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Self-citationSun, J. C., Lopez-Verges, S., Kim, C. C., DeRisi, J. L., & Lanier, L. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003035 · Cited by 211
Tesi, B., Davidsson, J., Voss, M., Rahikkala, E., Holmes, T. D., Chiang, S. C. C., Komulainen-Ebrahim, J., Gorcenco, S., Rundberg Nilsson, A., Ripperger, T., et al. (2017) · Blood · doi:10.1182/blood-2016-10-743302 · Cited by 207
Engineering lymphocyte subsets: tools, trials and tribulations
June, C. H., Blazar, B. R., & Riley, J. L. (2009) · Nature Reviews Immunology · doi:10.1038/nri2635 · Cited by 204
Shah, N., Martin-Antonio, B., Yang, H., Ku, S., Lee, D. A., Cooper, L. J. N., Decker, W. K., Li, S., Robinson, S. N., Sekine, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076781 · Cited by 199
Self-citationSahm, C., Schönfeld, K., & Wels, W. S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1212-x · Cited by 186
Gill, S., Vasey, A. E., De Souza, A., Baker, J., Smith, A. T., Kohrt, H. E., Florek, M., Gibbs, K. D., Tate, K., Ritchie, D. S., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415364 · Cited by 183
Influence of SHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation
Wang, J.-W., Howson, J. M., Ghansah, T., Desponts, C., Ninos, J. M., May, S. L., Nguyen, K. H. T., Toyama-Sorimachi, N., & Kerr, W. G. (2002) · Science · doi:10.1126/science.1068438 · Cited by 178
Mishra, A., Liu, S., Sams, G. H., Curphey, D. P., Santhanam, R., Rush, L. J., Schaefer, D., Falkenberg, L. G., Sullivan, L., Jaroncyk, L., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.009 · Cited by 169
Rouce, R. H., Shaim, H., Sekine, T., Weber, G., Ballard, B., Ku, S., Barese, C., Murali, V, Wu, M.-F., Liu, H., et al. (2016) · Leukemia · doi:10.1038/leu.2015.327 · Cited by 161
Self-citationAzuma, M., Cayabyab, M. J., Buck, D., Phillips, J. H., & Lanier, L. L. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.4.1115 · Cited by 150
Sun, J. C.-Y., Beilke, J. N., Bezman, N., & Lanier, L. L. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100479 · Cited by 146
Chen, X., Allan, D., Krzewski, K., Ge, B.-X., Kopcow, H. D., & Strominger, J. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604236103 · Cited by 134
Elpek, K. G., Rubinstein, M. P., Bellemare-Pelletier, A., Goldrath, A. W., & Turley, S. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012128107 · Cited by 130 · cited 1×
“Moreover, in contrast to a previous report in murine NK cells that sustained stimulation with IL-15/IL-15R-α complexes induces dysfunction,(29) human iC9/CAR.”
Huenecke, S., Zimmermann, S. Y., Kloeß, S., Esser, R., Brinkmann, A., Tramsen, L., Koenig, M., Erben, S., Seidl, C., Tonn, T., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181bb46f7 · Cited by 104
Cany, J., van der Waart, A. B., Tordoir, M., Franssen, G. M., Hangalapura, B. N., de Vries, I. J. M., Boerman, O. C., Schaap, N. P., van der Voort, R., Spanholtz, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064384 · Cited by 94
Galea‐Lauri, J., Darling, D. C., Gan, S. U., Krivochtchapov, L., Kuiper, M., Gäken, J. A., Souberbielle, B. E., & Farzaneh, F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.62 · Cited by 85
Sekine, T., Marin, D., Cao, K., Li, L., Mehta, P., Shaim, H., Sobieski, C. E., Jones, R. B., Oran, B., Hosing, C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-706317 · Cited by 61
Self-citationKruse, V., Hamann, C., Monecke, S., Cyganek, L., Elsner, L., Hübscher, D., Walter, L., Streckfuß‐Bömeke, K., Guan, K., & Dressel, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125544 · Cited by 58
Corat, M. A. F., Schlums, H., Wu, C., Theorell, J., Espinoza, D. A., Sellers, S. E., Townsley, D. M., Young, N. S., Bryceson, Y. T., Dunbar, C. E., et al. (2016) · Blood · doi:10.1182/blood-2016-08-734285 · Cited by 46
Immunotherapeutic Approaches for Hematologic Malignancies
Caligiuri, M. A., Velardi, A., Scheinberg, D. A., & Borrello, I. (2004) · Hematology · doi:10.1182/asheducation-2004.1.337 · Cited by 43
Analysis of the NK Cell Immunological Synapse
Sanborn, K. B., Rak, G. D., Mentlik, A. N., Banerjee, P. P., & Orange, J. S. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-362-6_9 · Cited by 20
Self-citation
Cited by
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Self-citationExploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Metadata
- Authors
- Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., Gagea, M., Banerjee, P., Cai, R., Bdaiwi, M. H., Basar, R., Muftuoglu, M., Li, L., Marin, D., Wierda, W., Keating, M., Champlin, R., Shpall, E., & Rezvani, K.
- Venue
- Leukemia
- Published
- 2017-07-20
- Volume
- 32
- Issue
- 2
- Pages
- 520-531
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2738977754
- Cited by
- 824
- References
- 51
- FWCI
- 21.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.